BOOST Pharma Installs New CEO to Steer BT-101 Toward Late-Stage Trials in Brittle Bone Disease

New updates have been reported about BOOST Pharma.

BOOST Pharma has appointed board member Hans Schambye, MD, PhD, as its new full-time Chief Executive Officer, positioning the company for its next stage of growth as it advances BT-101, an off-the-shelf cell therapy for osteogenesis imperfecta (OI). Schambye, a veteran biotech leader who previously ran Galecto Inc. and raised more than $500 million there, brings deep experience in clinical development, financing strategy, and operational scaling from discovery through late-stage trials.

The leadership change comes as BOOST prepares BT-101 for Phase III studies in children with severe OI (Type III and IV), following Phase I/II data showing more than a 70% fracture reduction in the first year and roughly 78% in the second year, with most patients fracture-free in year two. BT-101, an allogeneic mesenchymal stem cell therapy with Orphan Drug Designation in the U.S. and Europe, targets the underlying biology of OI in a market where no disease-modifying therapies are approved, giving BOOST a potentially first-in-class, high-value asset backed by a syndicate of life-science investors and a management team tasked with capital-efficient development and clear regulatory and commercialization pathways.